FSD Pharma Inc
Change company Symbol lookup
Select an option...
HUGE FSD Pharma Inc
GWPAX American Funds Growth Portfolio Class A
LIXTW Lixte Biotechnology Holdings Equity Warrants Exp 1st Jan 2025 *W EXP 01/01/2025
ZIONP Zions Bancorporation NA
BLK BlackRock Inc
GTEH Gentech Holdings Inc
$SPCOMBULD S&P 1500 Building Products(Sub Ind)
KELYA Kelly Services Inc
SONY Sony Group Corp
BVNRY Bavarian Nordic A/S
Go

Health Care : Pharmaceuticals | Small Cap Value
Based in Canada
Company profile

FSD Pharma Inc. is a Canada-based biotechnology company. The Company, through its subsidiary, FSD Biosciences Inc., is focused on pharmaceutical research and development (R&D) of its compound, ultra-micronized palmitoyl ethylamine (PEA). The Company, through its wholly owned subsidiary, Lucid Psycheceuticals Inc. (Lucid), is also focused on the research and development of its lead compounds, Lucid-PSYCH and Lucid-MS. Lucid PSYCH is a molecular compound identified for the potential treatment of mental health disorders. Lucid-MS is a molecular compound identified for the potential treatment of neurodegenerative disorders. The Company’s wholly owned subsidiaries include Prismic Pharmaceuticals Inc. and FV Pharma Inc.

Closing Price
$0.90
Day's Change
-0.0224 (-2.43%)
Bid
--
Ask
--
B/A Size
--
Day's High
0.9376
Day's Low
0.89
Volume
(Light)
Volume:
37,892

10-day average volume:
80,802
37,892

Display:

Providers:

UpdateCancel
6 providers
May 11, 2022
InvestmentPitch Media Video Discusses FSD Pharma, a Life Sciences Holding Company, and the Closing of its Sale of Non-Core Assets for $16.4 million

EQNX::TICKER_START (CNSX:HUGE),(NASDAQ:HUGE),(Frankfurt:0K9A), EQNX::TICKER_END FSD Pharma Inc. (NASDAQ:HUGE) (CSE:HUGE) (FSE:0K9A), a life sciences holding company dedicated to building a portfolio of assets and biotech solutions, has closed the...(Globe Newswire)

May 10, 2022
FSD Pharma Closes CAD$16.4 Million Sale of Non-Core Assets

FSD Pharma Inc. (NASDAQ: HUGE) (CSE: HUGE) (FRE: 0K9A) ("FSD Pharma" or the "Company"), a life sciences holding company dedicated to building a portfolio of assets and biotech solutions, is pleased to announce today the closing of the sale of the...(BusinessWire)

May 06, 2022
FSD Pharma Announces Dismissal of Derivative Complaint

FSD Pharma Inc. (NASDAQ: HUGE) (CSE: HUGE) (FRA: 0K9) ("FSD Pharma" or the "Company"), a life sciences holding company dedicated to building a portfolio of assets and biotech solutions, announced today that the Company was successful in its motion...(BusinessWire)

May 02, 2022
FSD Pharma Announces Engagement with Tekkfund Capital and Share Issuance to Crystal Research Associates

FSD Pharma Inc. (NASDAQ: HUGE) (CSE: HUGE) (FRE: 0K9A) ("FSD Pharma" or the "Company"), a life sciences holding company dedicated to building a portfolio of assets and biotech solutions, announced today that on April 15th, 2022, the Company entered...(BusinessWire)

April 21, 2022
FSD Pharma Appoints Julia Levy Award Recipient David Allan and Dr. John McGraw to Advisory Board

FSD Pharma Inc. (NASDAQ: HUGE) (CSE: HUGE) (FRE: 0K9A) ("FSD Pharma" or the "Company"), a life sciences holding company dedicated to building a portfolio of assets and biotech solutions, announced the appointment of David Allan and John McGraw, PhD...(BusinessWire)

April 08, 2022
FSD Pharma Announces Cancellation of Certain Shares Issued to Former Chief Executive Officer Dr. Raza Bokhari

FSD Pharma Inc. (NASDAQ: HUGE) (CSE: HUGE) (FRA: 0K9A) ("FSD Pharma" or the "Company"), a life sciences holding company dedicated to building a portfolio of assets and biotech solutions, announced today, pursuant to a court endorsement, the...(BusinessWire)

April 06, 2022
FSD Pharma Issues Corporate Updates

FSD Pharma Inc. (NASDAQ: HUGE) (CSE: HUGE) (FRA: 0K9A) ("FSD Pharma" or the "Company"), a life sciences holding company dedicated to building a portfolio of assets and biotech solutions, announced today the following corporate updates; (BusinessWire)

March 31, 2022
FSD Pharma Announces Filing of Year-End 2021 Results

FSD Pharma Inc. (NASDAQ: HUGE) (CSE: HUGE) (FRA: 0K9) ("FSD Pharma" or the "Company"), a life sciences holding company dedicated to building a portfolio of assets and biotech solutions, announced today the filing of its Annual Report on Form 20-F...(BusinessWire)

March 15, 2022
FSD Pharma Announces Executive Informational Overview Report Produced by Crystal Research Associates LLC

FSD Pharma Inc. (NASDAQ: HUGE) (CSE: HUGE) (FRA: 0K9A) ("FSD Pharma" or the "Company"), a life sciences holding company dedicated to building a portfolio of assets and biotech solutions, announced today that Crystal Research Associates LLC has...(BusinessWire)

February 25, 2022
FSD Pharma Announces Agreement for Sale of Cobourg Facility for CAD$16,500,000

FSD Pharma Inc. (NASDAQ: HUGE) (CSE: HUGE) (FRA: 0K9A) ("FSD Pharma" or the "Company"), a life sciences holding company dedicated to building a portfolio of assets and biotech solutions, announced today that it has entered into a firm agreement in...(BusinessWire)

Earnings Calendar and Events Data provided by |Terms of Use| © 2022 Wall Street Horizon, Inc.

Market data accompanied by is delayed by at least 15 minutes for NASDAQ, NYSE MKT, NYSE, and options. Duration of the delay for other exchanges varies.
Market data and information provided by Morningstar.

Options are not suitable for all investors as the special risks inherent to options trading may expose investors to potentially rapid and substantial losses.
Please read Characteristics and Risks of Standard Options before investing in options.

"Hot" indicates urgent and noteworthy news stories as determined by providers Dow Jones or Benzinga. TD Ameritrade does not select or recommend "hot" stories.

Information and news provided by ,, , Computrade Systems, Inc., ,, and

Copyright © 2022. All rights reserved.